Advanced Search:
Equity Index Forex Crypto Commodity

JAZZ - Jazz Pharmaceuticals plc

$109.46  2.03 (1.89%)

Updated: 23:23 Apr 28, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

Jazz Pharmaceuticals plc's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

JAZZ PHARMACEUTICALS PLC - HISTORICAL DATA 6M

  • Last price

    $ 109.46

  • Daily change

    $ 2.03

  • Previous Close

    $ 107.43

  • Last Updated

    23:23 Apr 28, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.36 -0.22 -0.14 -0.1

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 1.17 1.28 1.42 1.21

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A 100% 33.81% 9.19%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 108.94 -4.89% 114.54 -5.43% 121.12

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.42 50.25 0.52 29.58

Jazz Pharmaceuticals plc Technical Analysis News

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin 4
Ireland
353 1 634 7800
https://www.jazzpharma.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 2800
Description

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Corporate Governance

Jazz Pharmaceuticals plc’s ISS Governance QualityScore as of January 28, 2024 is 3. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 3; Compensation: 4.

JAZZ PHARMACEUTICALS PLC'S HOLDERS RANK

List of holders with stock participation in Jazz Pharmaceuticals plc.

Holder Rank Holder Shares Date Reported % Out Value